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Vascular endothelial growth factor (VEGF) is one of the most important regulators of physiological and pathological
angiogenesis. Constitutive activation of the extracellular signal-regulated kinase (ERK) pathway and overexpression of
VEGF are common denominators of tumors from different origins. We have established a new link between these two
fundamental observations converging on VEGF mRNA stability. In this complex phenomenon, tristetraprolin (TTP), an
adenylate and uridylate-rich element-associated protein that binds to VEGF mRNA 3-untranslated region, plays a key
role by inducing VEGF mRNA degradation, thus maintaining basal VEGF mRNA amounts in normal cells. ERKs
activation results in the accumulation of TTP mRNA. However, ERKs reduce the VEGF mRNA-destabilizing effect of
TTP, leading to an increase in VEGF expression that favors the angiogenic switch. Moreover, TTP decreases RasVal12-
dependent VEGF expression and development of vascularized tumors in nude mice. As a consequence, TTP might
represent a novel antiangiogenic and antitumor agent acting through its destabilizing activity on VEGF mRNA. Deter-
mination of TTP and ERKs status would provide useful information for the evaluation of the angiogenic potential in
human tumors.
INTRODUCTION
The formation of new blood vessels is essential for tissue
growth, expansion, and metastasis (Risau, 1996). Vascular
endothelial growth factor (VEGF) is a key mediator of phys-
iological and pathological angiogenesis (Ferrara, 2002). In-
creased production of VEGF has been shown to occur by
both transcriptional and posttranscriptional mechanisms
(Ferrara, 1999). Post-transcriptional regulation is emerging
as an important control point for gene expression in tumors
(Nabors et al., 2001). This regulation involves mRNA bind-
ing proteins that act on cis elements located in the 5- or
3-untranslated regions (UTRs) of mRNAs to alter mRNA
stability or the efficiency of translation (Tourriere et al.,
2002). VEGF mRNA-binding proteins have been described
previously as stabilizing or destabilizing factors. Some of
them are heterogeneous nuclear ribonucleoprotein (RNP) L
(Shih and Claffey, 1999), Elav protein HuR (Levy et al., 1998),
poly(A)-binding protein-interacting protein 2 (Onesto et al.,
2004), and tetradecanoyl phorbol acetate-inducible-sequence
11b (TIS11b) (Ciais et al., 2004). Another member of the TIS11
family, tristetraprolin (TTP), which presents with TIS11b
70% homology in the RNA binding domain but only an
average of 20% homology in the rest of the protein, is also
involved in the regulation of labile mRNA turnover. TTP has
been described as an mRNA-destabilizing protein that neg-
atively regulates the expression of proinflammatory media-
tors such as tumor necrosis factor , granulocyte–macroph-
age colony-stimulating factor (Carballo et al., 2000), interleukin
(IL)-2 (Raghavan et al., 2001), cyclooxygenase 2 (Sully et al.,
2004), and inducible nitric-oxide synthase (Fechir et al.,
2005). TTP exerts its action by binding to cis-acting elements
that are adenylate and uridylate-rich elements (AREs) (Shaw
and Kamen, 1986). The mitogen-activated protein kinase p38
regulates the stability of TTP protein in myeloid cells and
synergizes with the extracellular signal-regulated kinases
(ERKs) to regulate expression of TTP at a posttranslational
level (Brook et al., 2006). TTP acts as a potent tumor sup-
pressor when overexpressed in a v-H-Ras–dependent mast
cell tumor model (Stoecklin et al., 2003). One of the best-
characterized signaling pathways directly activated by Ras
involves Raf-1, mitogen-activated protein kinase kinase
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(MEK), and ERKs. The ERK pathway is central to a variety
of cellular processes, including proliferation, differentiation,
and survival. The ERK pathway plays a critical role in the
regulation of VEGF expression (Pages and Pouyssegur,
2005). Constitutive activation of either Ras or Raf, which
leads to constitutive activation of ERKs, allows tumor cells
to evade from both normal growth and apoptosis. The link
among ERK activity, the angiogenic switch, and VEGF
mRNA regulation deserved to be carefully investigated. In
this regard, we showed that TTP regulates VEGF mRNA
expression at the posttranscriptional level and blocks VEGF
expression in Ras-transformed cells in vivo. Our study es-
tablishes that ERKs control the degradative potential of TTP
in the context of regulation of VEGF mRNA stability.
MATERIALS AND METHODS
Plasmid Constructs
The VEGF 3-UTR/Luciferase constructs (Ciais et al., 2004) and the plasmids
used to prepare NsiI, and NsiI probes (Onesto et al., 2004) have been
described previously. pCDNA4/TO/mycTTP vector was generated by insert-
ing a 1-kb DNA fragment corresponding to the coding region of the TTP
cDNA (Stoecklin et al., 2003) within EcoRI and AgeI sites of the pCDNA4/TO.
The pGEX6P1/TTP vector was constructed by inserting an EcoRI/EcoRI 2-kb
fragment corresponding to the TTP coding region plus a portion of the initial
hphMX-TTP vector (Stoecklin et al., 2003) within the EcoRI sites of the
pGEX6P1 vector (GE Healthcare, Chalfont St. Giles, United Kingdom).
Antibodies
Monoclonal antibodies (anti-myc, 9E10 and anti-phospho ERKs) were from
Sigma (L’Isle d’Abeau, Chesnes, France) and Santa Cruz Biotechnology (Santa
Cruz, CA), respectively, and anti-pan-Ras was from Calbiochem (San Diego,
CA). The monoclonal anti-CD31 rat antibody was from BD Biosciences (Hei-
delberg, Germany). Glutathione transferase (GST)/TTP fusion protein was
used to produce a Rabbit polyclonal antibody according to standard proce-
dures (Eurogentec, Liege, Belgium). Horseradish peroxidase-conjugated anti-
mouse and anti-rabbit antibodies were purchased from Promega (Madison,
WI).
Cell Culture, Transfection, and Luciferase Assays
The Raf1-ER chimera, the A431 and Ras/Val12 (clone 5C) cells were grown as
described previously (Milanini-Mongiat et al., 2002). Transfections were car-
ried out using the calcium phosphate technique. S19R443 cells that express the
Tet repressor were used for transfection with pCDNA4/TO/myc-HisA
(pcDNA4/TO-TTP) (pTrex-A; Invitrogen, Cergy Pontoise, France). Zeocine-
resistant clones were screened by immunofluorescence and Western blotting
after tetracycline induction. Raf1-ER/TTP cells were cotransfected with a
plasmid coding for an activated form of the Ha-Ras oncogene (Seuwen et al.,
1988) and a plasmid coding for a puromycin resistance gene.
Transfection for luciferase assays were performed using 293Raf1-ER cells.
Eight hours after transfection, cells were serum starved for 14 h, followed by
stimulation or not with 1 M tamoxifen for 5 h. Luciferase assays were
performed as described previously (Milanini-Mongiat et al., 2002). Results
were expressed as the percentage of inhibition over control cells.
RNA Preparation, Real-Time Polymerase Chain Reaction
(PCR), and Northern Blotting
Total RNA was extracted with TRIzol Reagent (Invitrogen). Two micrograms
of total RNA were used for reverse transcription, using the Superscript
First-Strand Synthesis System (QIAGEN, Hilden, Germany), with oligo(dT) to
prime first-strand synthesis. For real-time PCR, primers and dual-labeled
probes (5-5-carboxyfluorescein, 3-5-carboxytetramethylrhodamine) were
from Applied Biosystems (7300 Software System; Courtaboeuf, France). To
calculate the relative expression of VEGF mRNA in Raf1-ER/TTP cells the
2[C(T)] method was used (Livak and Schmittgen, 2001). Northern Blots
were performed as described previously (Onesto et al., 2004).
5,6-Dichlorobenzimidazole Riboside (DRB) Pulse Chase
Experiments
Raf1-ER cells expressing inducible myc-tagged TTP were stimulated or not
with 1 g/ml tetracycline for 24 h before the addition of 25 g/ml DRB and
RNAs were prepared from 0 to 4 h thereafter. Relative VEGF and 36B4 mRNA
amounts were determined by quantitative reverse transcription-PCR, and
VEGF mRNA was normalized to 36B4 mRNA. The relative amounts of VEGF
mRNA at time 0 before DRB addition were set to 100%.
RNA Interference Experiments
TTP small interferring RNAs (siRNAs) (Eurogentec) were designed in differ-
ent regions of mouse TTP cDNA (NM 011576). The respective sequences are
as following: TTP (1): 5-UCGCCACCCCAAGUACAAAtt-3 and TTP (2):
5-CUCUGCCACAAGUUCUACCtt-3. The control siRNA (Dharmacon RNA
Technologies, Lafayette, CO) was used as an irrelevant siRNA. Raf1-ER cells
were transfected with siRNA as described previously (Onesto et al., 2004).
Forty-eight hours after the second transfection, cells were serum starved and
stimulated at indicated times with or without tamoxifen. Then, cells were
analyzed for the expression of TTP and VEGF mRNAs by real-time PCR.
Measurement of Secreted VEGF
VEGF protein release was measured using an enzyme-linked immunosorbent
assay (ELISA) kit Quantikine Mouse VEGF Immunoassay (R&D Systems,
Minneapolis, MN).
Immunoprecipitation of Ribonucleoprotein Complexes
RNP complexes were immunoprecipitated as described previously
(Niranjanakumari et al., 2002) by using protein G-Sepharose beads prein-
cubated with anti-myc antibody (9E10) or with an irrelevant antibody
(anti-Pan-Ras) (Calbiochem). RNA was isolated from supernatants and
immunoprecipitates and reverse-transcribed with Superscript II (Invitro-
gen). The transcripts were amplified by PCR by using the following
primers (5 to 3): VEGF, 5-ATGGCAGAAGGAGGGCAGCAT-3 and 5-
TTGGTGAGGTTTGATCCGCATCAT-3; and 36B4, 5-GCCAACCGCG-
AGAAGATGACCCAG-3 and 5-CTCGAAGTCCAGGGCGACGTAGC-3.
The PCR products were analyzed by 2% agarose gels.
Western Blot Analysis, Alkaline Phosphatase (Calf
Intestine Phosphatase [CIP]) Treatment, and
Cycloheximide Pulse Chase
Cell extracts were prepared in Laemmli buffer, resolved by SDS-polyacryl-
amide gel electrophoresis (PAGE), and transferred onto a polyvinylidene
difluoride membrane (Immobilon-P; Millipore, Billerica, MA). The immuno-
reactive proteins were visualized by the enhanced chemiluminescence detec-
tion system (ECL; Pierce Chemical, Rockford, IL). For experiments with CIP
(New England Biolabs, Ipswich, MA), Raf1-ER/TTP cells were first serum
starved and stimulated with 1 g/ml tetracycline for 24 h before stimulation
or not with 1 M tamoxifen for 3 h. Cells were then lysed in lysis buffer (1%
Triton X-100, 50 mM Tris, pH 8.5, 100 mM NaCl, and 0.5 mM EDTA). CIP (35
U) was added to the lysates for 1 h at 37°C. The reaction was stopped by
adding Laemmli sample buffer.
For cycloheximide pulse chase, cells were cultured in the same conditions.
After stimulation with tamoxifen for 3 h, Raf1-ER/TTP cells were treated with
10 g/ml cycloheximide to block protein neosynthesis in the presence or
absence of 10 M U0126.
RNA Electromobility Shift Assays (REMSAs)
RNA transcripts were synthesized as described previously (Levy et al., 1996).
For REMSA experiments, 30 pmol of biotinylated RNA using Biotin RNA
Labeling Mix (Roche, Penzberg, Germany) or radiolabeled RNA transcripts
(200,000 cpm/reaction) was combined with 50 nM GST fusion proteins or
GST alone, in a previously described binding buffer (Levy et al., 1996). The
reaction mixture was incubated for 30 min at 30°C and treated for 15 min at
room temperature with 100 U of ribonuclease T1 (Roche). When specific or
nonspecific competitors were used, they were incubated for 15 min at 30°C
with the proteins in binding buffer before the addition of the radiolabeled or
biotinylated transcripts. The reaction mixtures were resolved on 5% native
polyacrylamide gels in 0.5 Tris borate-EDTA (TBE) buffer. Gels were dried
and autoradiographed or transferred to nylon N membranes in 0.5 TBE at
400 mA and 4°C for 1 h. The RNAs were cross-linked to the membranes and
detected by the Lightshift electrophoretic mobility shift assay kit (Pierce
Chemical) by using streptavidin-horseradish peroxidase binding and chemi-
luminescent detection.
Tumorigenicity Assays
Raf1-ER/TTP (106) cells transformed by Ha-Ras were injected subcutaneously
in the flank of 6-wk-old nude (nu/nu) mice (Harlan, Indianapolis, IN).
Doxycycline (750 g/ml) was added to the drinking water starting from day
3 after the injection. Tumors were measured at the indicated times, and
volumes were calculated as v  L  l2  0.52 (Auerbach et al., 1978), where
L and l represent the largest and the smallest tumor diameter, respectively,
measured weekly. The observations were ended after 5 wk from the day of
cells injection. Animals were killed, and tumors were immediately frozen in
dry ice or fixed in Formalin. Care of the animals was provided according to
institutional guidelines: European Directive 86/609/EEC.
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Immunofluorescence Experiments
Cells and tumor sections (6-m cryostat sections) were fixed in 4% parafor-
maldehyde for 20 min at room temperature or cold acetone for 2 min,
permeabilized with 0.2% Triton X-100 for 5 min, and blocked in 2% bovine
serum albumin/phosphate-buffered saline (PBS) for 2 h. Cells or tumor
sections were then incubated with the appropriate antibody for 1 h at room
temperature. After three washes in PBS, cells were incubated with the appro-
priate fluorescent-conjugated secondary antibody or streptavidin conjugates
or with Cy3-conjugated mouse anti-rat IgG (Jackson ImmunoResearch Labo-
ratories, West Grove, PA), washed, and counterstained with 4,6-diamidino-
2-phenylindole (Vector Laboratories, Burlingame, CA). Preparations were
mounted in PBS:glycerol (1:9), analyzed with a Leica microscope (Leica,
Wetzlar, Germany), and counted at a 20 magnification in six random fields
from the tumor.
RESULTS
Increased VEGF mRNA Stability in Tumor Cell Lines with
High ERK1/2 Activity
Although numerous studies, including ours, have described
the role of ERKs on VEGF gene transcription (Milanini et al.,
1998), nobody has reported the impact of ERKs activity on
VEGF mRNA stability. For that purpose, we analyzed the
ERK1/2 activity and VEGF mRNA half-life in normal Chi-
nese hamster fibroblasts (control cells), as well as in Ras-
Val12-transformed cells (clone 5C) containing high amounts
of the transgene, a cellular system where ERKs activity is
increased. As shown in Figure 1A, ERK1/2 activity mea-
sured with anti-phospho–specific antibodies, is increased by
almost six times in Ras cells compared with control cells
(Figure 1A). VEGF mRNA expression and stability were
examined by Northern blotting on the different cell lines by
using DRB chase experiments (Figure 1B). Quantification of
all the VEGF mRNA isoforms (see arrows; Milanini et al.,
1998) detected in these experiments illustrates not only an
increase in VEGF mRNA amounts at the basal level but also
an increase in VEGF mRNA half-life in Ras (t1/2  168
min  10 min; p  0.05) compared with normal cells (t1/2 
27 min  5 min; p  0.05) (Figure 1C), indicating that an
increase in ERK1/2 activity is correlated to an increase in
VEGF mRNA stability. Equivalent results were obtained
with A431 cells that highly expressed EGF receptor and
present with constitutive ERK activity.
Specific Stabilization of VEGF mRNA by ERK Pathway
To more carefully address the relationship between ERK
activity and VEGF mRNA stability, we have used CCL39
Chinese hamster fibroblasts expressing the Raf1-ER chimera
(Lenormand et al., 1996). In these cells, tamoxifen stimula-
tion only results in the stimulation of ERKs. As described
previously (Milanini et al., 1998), after an overnight serum
starvation (null ERKs activity, Figure 2A), VEGF mRNAs
Figure 1. Expression of VEGF mRNA in normal and tumor cell
lines. (A) Twenty micrograms of total protein extracts from control
or Ras Val 12 (clone 5C)-transformed cells were subjected in dupli-
cate to Western blotting by using a monoclonal pERK antibody. The
amounts of actin are shown as a loading control. Average ERK
activity normalized to actin amounts obtained by quantification of
the two independent samples is also shown. (B) Total RNA isolated
from normal Chinese hamster fibroblasts and Ras Val 12 (clone 5C)
cells were analyzed by Northern blotting for the expression of VEGF
mRNA after DRB treatment (25 g/ml). 36B4 RNA is shown as a
loading control. (C) The amount of VEGF mRNA was quantified with
a PhosphorImaging system (Storm 840; Amersham Biosciences,
Roosendaal, The Netherlands). VEGF mRNA half-lives, deduced from
two independent experiments, are indicated (p  0.05).
Figure 2. VEGF mRNA expression is regulated by the ERK path-
way. (A) Raf1-ER cells were serum starved and treated with 1 M
tamoxifen for 3 h. Then, cells were treated or not with 10 M U0126.
Protein extracts (20 g) were analyzed by Western blotting by using
a monoclonal anti-pERK antibody. Data are representative of two
independent experiments. (B) Raf1-ER cells were serum starved and
treated with 1 M tamoxifen for 3H. Cells were treated with 25
g/ml DRB in the presence or absence of 10 M U0126. VEGF
mRNA was detected by Northern blotting and normalized against
36B4 RNA. (C) The amount of VEGF mRNA was quantified with a
PhosphorImaging system. VEGF mRNA half-lives, deduced from
two independent experiments, are indicated (p  0.05).
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were undetectable in these cells. To verify that VEGF mRNA
stabilization is specifically caused by ERKs activation, cells
were serum starved overnight and stimulated with tamox-
ifen for 3 h to allow VEGF mRNA accumulation. This VEGF
mRNA accumulation is due in part to transcriptional acti-
vation (Milanini et al., 1998). We have tested whether it also
could implicate mRNA stability mechanisms. Hence, the
rate of VEGF mRNA decay was evaluated by DRB chase
experiments in the presence or absence of the MEK inhibitor
U0126 at indicated times. Northern blot analysis showed
that when ERKs are permanently activated by tamoxifen
treatment, the half-life of VEGF mRNA (t1/2  225 min  10
min; p  0.05; Figure 2, B and C) was comparable with the
half-life observed in Ras-transformed cells (t1/2 168 min
10 min; p  0.05; Figure 1C). Inhibition of ERKs by U0126
resulted in a rapid decay of VEGF mRNA (t1/2  68 min 
5 min; p  0.05), confirming the results of Figure 1 showing
that ERKs activity is directly implicated in VEGF mRNA
stabilization. Figure 2A shows that, in Raf1-ER cells, ERKs
activity is stimulated by tamoxifen and that U0126 is able to
repress tamoxifen-induced ERKs activation.
Induction of TTP and VEGF mRNAs Is Dependent on
ERKs Activation
The previous results suggest that the ERK pathway may be
able to induce or activate proteins implicated in VEGF
mRNA stability or to repress or inactivate proteins impli-
cated in VEGF mRNA degradation. We then focused our
attention on negative regulators of VEGF mRNA stability
and particularly on the TTP protein for two reasons. First,
TTP is a destabilizing-mRNA binding protein acting
through AREs and reported to be a substrate for multiple
kinases, including ERKs, c-Jun NH2-terminal kinase, p38,
and MAPKAP kinase 2 (Brook et al., 2006). Second, VEGF
mRNA 3-UTR contains putative binding sites for TTP, sug-
gesting that TTP may be implicated in the regulation of
VEGF mRNA stability. Thus, we tested the impact of acti-
vation of the ERK pathway on TTP expression in Raf1-ER
cells stimulated by tamoxifen. VEGF expression has also
been tested in parallel to establish a potential relationship
between both proteins. Figure 3A showed that tamoxifen
induced a strong and rapid accumulation of TTP mRNA and
protein peaking, respectively, at 1 and 2 h after stimulation
(Figure 3, A and B). Although the expression of TTP mRNA
decreased after 1 h, the amount of VEGF mRNA increases
exponentially. These experiments show that ERKs induce a
concomitant expression of TTP and VEGF mRNA. This ob-
servation suggests that ERKs promote simultaneously the
production of angiogenic factors as well as proteins puta-
tively responsible for their down-regulation, thus initiating a
negative feedback loop. The fact that both proteins are
present simultaneously implicates a subtle regulatory mech-
anism.
GST-TTP Interacts with the VEGF mRNA 3-UTR In Vitro
To test whether TTP could interact directly with the VEGF
mRNA 3-UTR, gel shift assays were performed using re-
combinant GST-TTP protein. Figure 4B shows that GST-TTP
binds to the entire rat VEGF mRNA 3-UTR (full-length
probe). No shifted band was observed with GST alone,
demonstrating the specificity of the interaction. To restrict
the interacting region, the 3-UTR was divided into several
regions (NsiI, NsiI [NsiI part containing most of the
AREs], Stu I, and HP probes) (Figure 4A and Supplemental
Figure 3SDB). RNA electrophoretic mobility shift assays
showed that GST-TTP protein interacts specifically with
NsiI, NsiI, and HP regions (Figure 4B and Supplemental
Figure 3SDB) and that Stu I construct failed to bind to the
fusion protein.
This interaction is specific, because it can be inhibited by
competition with 100 M excess of unlabeled specific probe
(Figure 4C and Supplemental Figure 3SDB). The same molar
excess of unlabeled nonspecific probe (3UTR-ERK) poorly
affects TTP interaction demonstrating the specificity of TTP
RNA binding.
TTP Interacts with Endogenous VEGF mRNA
To determine whether TTP/VEGF mRNA 3-UTR interac-
tion also occurs in a cellular context, Raf1-ER cells were
stably transfected with an expression vector encoding a
tetracycline inducible myc-tagged TTP. Figure 5A shows
tetracycline-inducible overexpression of myc-tagged TTP in
different clones of exponentially growing Raf1-ER/TTP
cells, treated or not with tetracycline for various times.
Moreover, we observed by immunofluorescence analysis
(Figure 5B) that ectopically expressed TTP displays the same
subcellular localization than the endogenous form of TTP
(Cao, 2004). To confirm that TTP not only interacts with
VEGF 3-UTR transcript in vitro but also with the endoge-
nous VEGF mRNA, we performed ribonucleoprotein com-
plexes immunoprecipitation experiments with whole cell
extracts from Raf1-ER/TTP cells. Figure 5C shows that im-
munoprecipitation of TTP results in the coprecipitation of
Figure 3. ERK activation induces the expression of TTP and VEGF
mRNA. (A) Raf1-ER cells were serum deprived, treated with 1 M
tamoxifen for the indicated time, and total RNAs were isolated.
Quantitative PCR was performed using specific primers for VEGF
and TTP. Fold induction of VEGF and TTP RNA is relative to time
0 after normalization to 36B4 in each sample. (B) Protein extracts (30
g) prepared in parallel, were analyzed by Western blotting by
using a polyclonal anti-TTP, monoclonal anti-pERK, and ERK anti-
bodies. Data are representative of three independent experiments.
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VEGF mRNA (lane 4, top). This coprecipitation is specific,
because immunoprecipitation with an irrelevant antibody or
using cells in which TTP was not induced does not copre-
cipitate VEGF mRNA (lanes 8, 10, 11, and 13, top). This in
vivo interaction was not influenced by the ERK pathway as
immunoprecipitation with specific antibody after U0126
treatment does not modify the amount of immunoprecipi-
tated VEGF mRNA level (lane 6, top). VEGF mRNA was
also detected in total RNA prepared from Raf1-ER/TTP cell
extracts used for immunoprecipitations (input, lanes 1&2).
Immunoprecipitation of TTP does not lead to coprecipita-
tion of a nonspecific transcript such as 36B4 RNA (lanes 4
and 6, bottom), which was used as a negative control. These
results provide convincing evidence that VEGF mRNA is
specifically associated with TTP in vivo but ERKs do not
influence its binding capacity.
TTP Overexpression Decreases Endogenous VEGF mRNA
Half-Life and VEGF Secretion: Influence of ERKs
TTP effect on endogenous VEGF mRNA stability was per-
formed by measuring the VEGF mRNA half-life by using
DRB chase experiments. The influence of ERKs was esti-
mated by stimulating the cells by tamoxifen in the absence
or presence of U0126. The amounts of VEGF mRNA were
evaluated by real-time PCR. As we demonstrated in Figure
2B, Figure 6A confirms that, in control cells, when ERKs
were activated by tamoxifen treatment (TET, U0, maxi-
mal ERKs activity), the half-life of VEGF mRNA was 4 h
(t1/2  240 min  20 min; p  0.05). Inhibition of ERKs by
U0126 (TET, U0, very low ERKs activity) resulted in
approximately fourfold decrease of VEGF mRNA half-life
(t1/2  60 min  7 min; p  0.05). When TTP was overex-
pressed and ERKs were activated (TET, U0, maximal
ERKs activity), VEGF mRNA half-life is almost the same
than in absence of TTP and even superior (t1/2 	240 min;
p  0.05). However, when TTP is overexpressed and ERKs
were inactivated by U0126 (TET, U0, very low ERK
activity), the half-life of VEGF mRNA is reduced by over
eightfold (t1/2  30 min  5 min; p  0.05). Supplemental
Figure 1SD shows that it exists a gradation in ERKs activity
in these different situations (i.e., growth-arrested cells 
treatment by U0126  exponentially growing cells  Ras-
transformed cells  tamoxifen-stimulated cells). These re-
sults strongly suggested that ERKs exert an inhibitory effect
on TTP. They also suggested a molecular link between ERKs
and TTP. Figure 6B (left) shows that tamoxifen stimulation
results in a shift in electrophoretic mobility of TTP. Phos-
Figure 4. TTP interacts with the VEGF mRNA 3-UTR in vitro. (A)
Schematic map of the VEGF 3-UTR illustrating the templates used
for generation of riboprobes for REMSA. (B) REMSAs were per-
formed by incubating the radiolabeled VEGF 3-UTR transcripts
(full length, NsiI, and NsiI) with purified GST-TTP or GST. The
arrows point to RNA–protein complexes. (C) Competition with
specific competitor (100 M excess) corresponding to unlabeled NsiI
and NsiI transcripts, respectively, was also performed in the pres-
ence of GST-TTP. The arrows point to RNA–protein complexes.
Figure 5. TTP interacts with VEGF mRNA in vivo. (A) Raf1-ER
cells were stably transfected with an expression vector encoding a
tetracycline inducible myc-tagged TTP. Cells were stimulated for
various times with 1 g/ml tetracycline. Inducible overexpression
of myc-TTP was then verified either by Western blotting or (B) by
immunostaining, by using a monoclonal anti-myc antibody. (C)
Tamoxifen-treated Raf1-ER/TTP cell extracts were immunoprecipi-
tated with no antibody, with the anti-myc antibody, or with an
irrelevant antibody (anti-Ras antibody) in the presence or absence of
MEK inhibitor 10 M U0126. Equal aliquots of purified total RNA
isolated from the immunoprecipitates (P), and from the superna-
tants (S), were assayed by reverse transcriptase-PCR to detect the
VEGF (top) and 36B4 (bottom) transcripts.
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phatase treatment induced a disappearance of the retarded
bands (Figure 6B, right), demonstrating that, in our experi-
mental model, tamoxifen stimulated ERKs induced TTP
phosphorylation, as already suggested (Brook et al., 2006). It
is important to note that upon tamoxifen treatment, TTP
amounts are increased compared with growth factor-de-
prived cells (null ERKs activity). This induction is specific,
because the MEK inhibitor UO126 blocks the accumulation
of both the endogenous and exogenous proteins (Figure 6C,
left and right, respectively). This also strongly suggested
that phosphorylation of TTP by ERKs results in increased
stability of the protein as it was previously described by
Brook et al. (2006). We have shown by cycloheximide pulse
chase experiments that it was effectively the case (Supple-
mental Figure 2SD). Altogether, our results suggested that
even if TTP is constitutively bound to VEGF mRNA, its
ERKs-dependent phosphorylation status is directly impli-
cated in its “degradative” action.
To correlate VEGF mRNA stability with VEGF produc-
tion, secreted VEGF was measured by ELISA in superna-
tants of exponentially growing cells (intermediate ERK ac-
tivity) overexpressing or not TTP (Raf1-ER/TTP, Raf1-ER).
Under these conditions, TTP is still able to reduce VEGF
mRNA stability. Figure 6D shows reduction of VEGF secre-
tion when TTP was overexpressed, whereas no inhibition
was detected in control cells. These results suggest that the
reduction in VEGF mRNA stability mediated by TTP corre-
lates with a decrease in VEGF production.
Silencing of TTP by RNA Interference Increases the Level
of Endogenous VEGF mRNA: Influence of ERKs
To strengthen the conclusions drawn from the contribution
of TTP in the regulation of VEGF mRNA expression, we
used the RNA interference methodology. Forty-eight hours
after transfection with two independent siRNA duplexes
targeting different regions of TTP mRNA, Raf1-ER cells were
treated or not with tamoxifen for the indicated periods in the
presence or absence of U0126. TTP and VEGF mRNA ex-
pression were evaluated by real-time PCR. Quantification of
TTP and VEGF mRNA level revealed that TTP gene expres-
sion was knocked down by 
50%, whereas nonspecific con-
trol siRNA (Dharmacon RNA Technologies) was ineffective
on TTP silencing (Figure 7A). In tamoxifen-treated cells,
control siRNA had no effect, because we obtained an equiv-
alent-fold stimulation as reported in Figure 3A (
3-fold
compared with untreated cells). However, TTP knockdown
with two independent siRNA resulted in an approximately
sevenfold increase of VEGF mRNA expression compared
with untreated cells (2.5-fold more than in the absence of
TTP-directed siRNA, Figure 7B). U0126, as expected, re-
duced the effects of tamoxifen in the presence of control
siRNA (1.5-fold induction). However, TTP directed siRNA
diminished the effect of U0126 (4-fold induction remaining
compared with control cells), suggesting that TTP is an
important mediator of VEGF mRNA down-regulation when
ERK activity is inhibited.
Figure 6. TTP overexpression decreases VEGF mRNA
half-life in vivo. (A) Raf1-ER/TTP cells were serum-
starved and stimulated () or not () with 1 g/ml
tetracycline for 24 h. After 3 h of stimulation with
tamoxifen, cells were incubated in the absence or pres-
ence of 10 M U0126 for one supplemental hour, and
then in the presence of 25 g/ml DRB for the indicated
times. During the DRB chase, cells were maintained or
not in the presence of U0126. The amounts of VEGF
mRNA remaining were quantified by real-time PCR.
The values are normalized to 36B4, and the values at
time 0 were taken as 100%. VEGF mRNA half-lives
were deduced from the curves (n  3; p  0.05). (B)
Raf1-ER/TTP cells were serum-starved and stimulated
with 1 g/ml tetracycline for 24 h before stimulation or
not with tamoxifen for indicated time. Left, time course
of tamoxifen stimulation. Arrow and bracket indicate
the unshifted and the retarded bands, respectively.
Right, cell extracts were treated or not with CIP. Protein
extracts (30 g) were then analyzed by Western blotting
by using anti-myc, pERK and ERK antibodies. This
experiment is representative of two independent exper-
iments. (C) Raf1-ER or Raf1-ER/TTP cells were serum
starved, stimulated with 1 M tamoxifen and incubated
in the absence or presence of 10 M U0126 for one
supplemental hour. Protein extracts (30 g) were ana-
lyzed by Western blotting using anti-TTP, myc, and
ERK antibodies. This experiment is representative of
two independent experiments. (D) Exponentially grow-
ing Raf1-ER or Raf1-ER/TTP cells were stimulated with
or without 1 g/ml tetracycline for 24 h. Secreted VEGF
was measured by ELISA. VEGF levels were normalized
to the cell number. -Fold inhibition of secreted VEGF
are presented as a mean of three independent experi-
ments performed in triplicate.
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TTP Induced an Inhibitory Effect on VEGF -3-UTR
Luciferase Reporter Gene: Influence of ERKs
To determine whether TTP exerts its effect via the VEGF
3-UTR, we have cloned downstream of luciferase reporter
gene different domains of VEGF mRNA 3-UTR. These con-
structs were transfected in 293 Raf1-ER cells, an easier
transfectable cell line (Cagnol et al., 2006). TTP induced a
dose-dependent inhibitory effect on luciferase activity on the
full-length 3-UTR, reaching 80% inhibition in serum de-
prived cells. Tamoxifen stimulation results in an increase of
luciferase activity demonstrating that ERKs are implicated
in VEGF mRNA stability through its 3-UTR. In the presence
of tamoxifen, TTP is still able to reduce luciferase activity but
to a lesser extent (Figure 8A). Thus, ERKs partially prevents
TTP-dependent degradation of VEGF 3-UTR reporter
mRNA. Experiments described in Figure 6B suggested that
it acts through a phosphorylation-dependent mechanism. To
evaluate through which domain(s) TTP exerts its action, the
effect of TTP was tested on different constructs of the rat
VEGF 3-UTR (Figure 8B). Figure 8C indicated that, whereas
TTP had no effect on luciferase activity mediated by a con-
trol vector, it principally inhibits the activity of the VEGF
3-UTR throughout the NsiI region. The Luc-HP construct,
which contains five AU consensus domains that form a
stable hairpin structure important for the posttranscriptional
regulation of VEGF (Page`s et al., 2000), similarly responded
to TTP, although slightly less than the full-length construct.
HP region contained two consensuses ARE motifs that are
both conserved in the human VEGF sequence. Mutations of
these two ARE alone or together do not affect the TTP effect
in contrast to TIS11b, the activity of which is dependent on
these ARE sequences (Ciais et al., 2004). Deletion of a large
fragment of the VEGF 3-UTR containing all ARE motifs
(StuI) did not abrogated the inhibitory effect of TTP on
reporter gene activity. This suggests the existence of an
indirect mode of regulation that does not depend on TTP
binding. The data of Supplemental Figure 3SD further sup-
port this interpretation as GST-TTP does not bind to the StuI
domain.
Overexpression of TTP in Ras Cells Decreases VEGF
Secretion
Because TTP negatively controls VEGF mRNA expression,
we hypothesized that, in tumor cells, TTP is down-regulated
or that its activity is inhibited. To validate this hypothesis,
we evaluated the role of TTP in neovascularization and
tumor growth in vivo by tumorigenesis assays on nude
mice. We first transfected Raf1-ER/TTP cells (having a low
tumorigenic potential) with a constitutively active form of
Ha-Ras and isolated stable clones expressing Ras Val 12. As
a negative control, we used the same cells transfected with
Figure 7. TTP knockdown increases VEGF mRNA level. (A) Cells
were transfected with siRNAs against TTP or with a control siRNA
(Dharmacon RNA Technologies). Forty-eight hours after the second
transfection, cells were serum starved overnight and stimulated
with tamoxifen for 3 h in the absence or presence of 10 M U0126.
Total RNA was isolated and real-time PCR analysis was performed
to determine TTP and (B) VEGF mRNA expression levels. The data
shown represent the mean  SE of three independent experiments.
Figure 8. TTP induced an inhibitory effect on luciferase activity.
(A) 293 Raf1-ER cells were cotransfected with a VEGF mRNA-3-
UTR-luciferase reporter construct and different amounts of TTP
expression plasmids in the presence or absence of 1 M tamoxifen.
Luciferase assays were conducted 24 h after transfection. Relative
luciferase activity was normalized to total protein amount. The
luciferase counts obtained with the construct Luciferase/VEGF 3-
UTR in the absence of TTP was taken as the value of reference
(100%). The percentages of inhibition exerted by TTP are also indi-
cated on the figure. Results are reported as the mean  SE of three
independent experiments performed in triplicate. (B) Mapping of
different sequences in VEGF mRNA 3-UTR used for TTP inhibition
of reporter gene activity. (C) Transfections were performed as de-
scribed in A in the presence or absence of 100 ng of TTP. The
luciferase values obtained for each construct in the absence of TTP
were taken as the value of reference (100%). Plotted are the percent-
ages of remaining luciferase activity in the presence of TTP. Results
are reported as the mean  SE of three independent experiments
performed in triplicate.
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an empty vector. As a positive control, we used Ras 5C cells
stably expressing the same active form of Ras (Seuwen et al.,
1988). Both expression of Ras Val 12 and TTP were verified
by Western blot. As shown in Figure 9A (left), all stable
clones selected expressed Ras and TTP after tetracycline
induction. Tetracycline treatment had no significant effect on
the expression of Ras Val 12. TTP expression remained in-
ducible by tetracycline in Ras Val 12-transformed cells. The
level of Ras Val 12 expression in these cells was estimated to
be 10 times lower than the levels found in Ras 5C cells.
VEGF secretion was then checked in exponentially growing
Raf1-ER/TTP-Ras and TTP control cells. It is important to
note that ERKs activity in exponentially growing Raf1-ER/
TTP-Ras cells is increased compared with control cells but
remains inferior than in tamoxifen-stimulated cells (Supple-
mental Figure 1). Hence, ERKs cannot exert a maximal in-
hibitory effect on TTP “degradative” activity. As shown in
Figure 9A (right), VEGF amounts in supernatants derived
from Raf1-ER/TTP-Ras cells was higher compared with con-
trol cells. After 24 h of tetracycline treatment, overexpression
of TTP was sufficient to lower VEGF production both in
control cells (Raf1-ER/TTP cells) and in Raf1-ER/TTP-Ras
cells by 65 and 45%, respectively. This result clearly shows
that TTP was still able to reduce VEGF production in Raf1-
ER/TTP-Ras cells. It is important to note that the inhibitory
effect of TTP is not equivalent in Raf1-ER/TTP-Ras and in
control cells. This inhibitory effect is directly proportional to
ERKs activity in both cell types (Supplemental Figure 1).
Overexpression of TTP Slows Down the Growth Rate of
Tumor Xenografts
To verify whether TTP, by reducing VEGF production, may
have an impact on tumor growth in vivo, we used Raf1-ER/
TTP-Ras cells to induce tumors in nude mice. We subcuta-
neously injected 106 cells into the flank of nude mice. As a
positive control, 105 cells from the Ras 5C cells were injected
into another group of mice. Then, mice were divided into
two experimental groups (n  8/group). Animals were
given doxycycline (Dox-treated group) or not (control
group) in their drinking water, starting 3 d after tumor cells
inoculation and for the whole duration of the experiment.
After injection, tumors were allowed to grow for 5 wk.
Subsequent tumor growth was monitored every week and
tumor volume calculated as indicated in Materials and Meth-
ods. We observed that doxycycline treatment had no non-
specific effect on the time required for emergence and
growth of 5C cells (data not shown). As shown in Figure 9B
(left), tumors resulting from the injection of inducible cells
emerged at day 15 in the control group. In contrast, at this
time, tumors were not yet visible in Dox-treated mice. Tu-
mors in these mice emerged only 2 wk later, and, in some
mice, tumors never developed. The growth rate of control
tumors was ninefold greater than in the doxycycline treated
mice. For ethical reasons, we decided to end the observa-
tions five weeks after injection. As shown in Figure 9B,
tumors in the control group had a median volume of 2494
mm3, which was 10-fold larger than the treated group (261
mm3). Tumor growth time was statistically significant (p 
0.0001) from day 15 after the beginning of doxycycline treat-
ment until the day the mice were killed. This correlates with
tumor weight that was reduced approximately by 12-fold in
Dox-treated mice. These data clearly show that inducible
expression of TTP is able to slow down the growth of
Ras-derived xenografts and that it has a lasting effect on
tumor development, being effective for at least 35 d.
Overexpression of TTP Reduces Intratumoral Hemoglobin
and VEGF
To determine whether the difference of growth between the
xenografts resulted from impaired angiogenesis, we both
monitored hemoglobin and VEGF contents in tumors. Fig-
Figure 9. Inducible expression of TTP inhibits tumor angiogenesis
in vivo. (A) Left, Raf-ER/TTP cells were transfected with a plasmid
coding for Ha-Ras. Cells from stable clones were stimulated for
various times with 1 g/ml tetracycline before lysis. Total cell
extracts were used to detect both Ras and myc-TTP proteins by
Western blot analysis by using anti-Pan Ras and Myc antibodies,
respectively. Protein levels of total ERK are shown as loading con-
trol. Right, supernatants from stable clones cultured in the presence
or absence of 1 g/ml tetracycline for 24 h were collected and
analyzed by mouse VEGF-specific ELISA. Results are reported as
the mean  SE of three independent experiments each run in
duplicate. (B) Left, eight nude mice per condition were inoculated
with cells from stable clone or negative and positive control. Ani-
mals were randomized into two groups. One group received weekly
750 g/ml doxycycline. Tumor size was measured at the indicated
times and tumor volume was calculated. The medians of the tumor
size (cubic millimeters) are indicated. Right, tumors were excised
from animals at day 35 after tumor cell inoculation when the largest
tumor had reached a diameter of 4 cm. Representative examples for
each experimental group are shown. (C) Tumor tissues were lysed and
intratumoral hemoglobin and VEGF contents were measured by Drab-
kin reagent kit 525 (Sigma) and ELISA (R&D systems), respectively.
The data were corrected to the protein concentration. (D) Immunoflu-
orescence staining of frozen tumor sections with anti-CD31 antibody.
Data are representative of two independent experiments.
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ure 9C (left) shows a 10-fold reduction of intratumoral he-
moglobin in Dox-treated xenografts compared with control.
Figure 9C (right) shows that control xenografts present with
higher VEGF levels compared with Dox-treated-tumors.
This decrease in VEGF amount correlate with the diminu-
tion observed in individual clones.
Dox-treated Tumors Have a Reduced Microvessel Density
Marked differences were observed both by morphological
analysis (Figure 9B, right) and by specific immunofluores-
cence staining (Figure 9D). Figure 9D shows that control
tumors seemed to be much more vascularized. In contrast,
treated tumors were almost white and did not show any
major vascular structure. These notable macroscopical dif-
ferences represent our first in vivo indication that TTP is able
to impair tumor growth rate by inhibiting angiogenesis.
Immunostaining for the endothelial cell marker CD31
showed that Dox-treated tumors exhibited low vascular
density compared with tumors from untreated mice (Figure
9D). Vessels from these tumors were generally thinner and
displayed multiple branched points. Equivalent results were
obtained by staining the tumors with von Willebrand factor
(data not shown).
DISCUSSION
VEGF production is one of the most important regulators of
tumor angiogenesis. Its expression, especially by oncogenes
was particularly investigated at the transcriptional level.
However, the relationship between oncogenes and VEGF
mRNA stability was poorly documented. In this report, we
have established a new molecular link between the Ras–Raf–
MEK–ERK pathway and VEGF mRNA stability. Thus, we
have described that the regulation of basal VEGF mRNA
amounts in normal cells is dependent on an active mecha-
nism involving the protein TTP, an ARE binding factor.
Several reports support the observations that activation of
several signaling pathway serve to stabilize ARE-containing
transcripts (Dean et al., 2004). Our data suggest that in tumor
cells, activation of the ERK pathway favors VEGF mRNA
stability. Interestingly, we have demonstrated that the ERK
pathway induces the expression of VEGF mRNA. It also
induces the expression of TTP, a potent protein inducing the
degradation of VEGF mRNA. We found that the 3 UTR of
VEGF mRNA contains independently functional destabiliz-
ing elements, not AU rich, and that the rapid degradation of
the VEGF mRNA is due to the combined action of these
elements. Our data are concordant with a previous report
(Marderosian et al., 2006) which showed that removal of
specific AUUUA motifs from the 3-UTR of Cyclin D1
mRNA resulted in transcripts that were still destabilized by
TTP. It may be expected that removal of these elements
would result in a transcript with increased stability as pre-
viously reported (Ciais et al., 2004) for TIS11b, the first
identified protein destabilizing VEGF mRNA. TIS11b acts
through a 75-base pair domain, containing two consensus
AU-rich motifs. This domain binds TIS11b and mediates its
destabilizing activity. In the present work, we show that TTP
could not only influence VEGF mRNA stability through this
domain but it also through other non-AUUUA regions (Fig-
ure 8C, Stu I region). We concluded that other sequences
besides the ARE were involved in the TTP-mediated overall
steady-state turnover of VEGF mRNA. It also demonstrated
that even if TTP and TIS11b belong to the same family of
proteins, their action on VEGF mRNA stability is not redun-
dant. Our data indicate that TTP action is probably indepen-
dent on RNA binding in mRNA devoid of ARE. Some VEGF
mRNA resulting from alternative utilization of polyadenyl-
ation sites and devoid of ARE sequences (Claffey et al., 1998)
could remain TTP sensitive. Nevertheless, TTP binds to
various elements located within the 3 UTR of VEGF mRNA
and facilitates the recruitment of the decay machinery, lead-
ing to message destabilization and reduced VEGF produc-
tion. However, activation of ERKs decreases this effect. It is
important to stress that TTP “degradative” effect is inversely
proportional to ERKs activity; TTP 100% activity (null ERKs
activity: serum deprived cells or U0126) 	 TTP strong
activity (basal ERKs activity: exponentially growing control
cells) 	 TTP intermediate activity (intermediate ERKs activ-
ity: exponentially growing Raf1-ER/TTP-Ras cells) 	 TTP
null activity (full ERKs activity: tamoxifen-stimulated Raf1-
ER/TTP cells) (Supplemental Figure 1SD). Our data are in
agreement with studies demonstrating that p38 activity is
antagonistic to ARE-directed deadenylation and subsequent
decay of the TNF mRNA (Dean et al., 2003). More recently,
Hitti et al. (2006) reported that mitogen-activated protein
kinase-activated protein kinase 2 regulates TNF mRNA sta-
bility and translation by altering TTP expression, stability,
and binding to ARE elements. One could imagine that ERKs
activity is essential for stabilization of TTP mRNA and pro-
tein as well as for stabilization of VEGF mRNA. Indeed, we
have observed that TTP is phosphorylated in response to
tamoxifen. Moreover, phosphorylation of TTP by ERKs re-
duces its proteasome-dependent degradation (Brook et al.,
2006) and increases its stability (Supplemental Figure 2SD).
Our results strongly suggested that ERKs-dependent phos-
phorylation events could also modulate the capacity of TTP
to induce mRNA degradation. However, this mechanism
does not depend on the ability of TTP to bind VEGF mRNA,
because we have observed that TTP in vivo binding is equiv-
alent upon tamoxifen stimulation in the presence or absence
of the MEK inhibitor U0126. A possible explanation for these
observations is that phosphorylation of TTP allows the re-
cruitment of other stabilizing proteins such as HuR, an
ARE-binding protein responsible for increased VEGF mRNA sta-
bility upon hypoxia (Levy et al., 1998). We are currently
investigating this point. More recently, Cherradi et al. (2006)
reported that TIS11b and HuR exert antagonistic effects on
VEGF 3-UTR in vitro. HuR seems to transiently stabilize
VEGF transcripts after ACTH stimulation of adrenocortical
cells, and TIS11b seems to subsequently trigger their degra-
dation. The impact of TTP on the development of Ras-
transformed cells has already been evaluated (Stoecklin et
al., 2003). Our study proposes an interpretation of these
previous results, demonstrating that angiogenesis and in
particular VEGF are key events. It is important to stress that
the antagonist role of ERKs on TTP activity is not high-
lighted in in vivo experiments. It is probably because the
intermediate ERKs activity observed in Raf1-ER/TTP-Ras is
not sufficient to totally antagonize TTP degradative action
(Figures 8A and 9A). Even if VEGF remains a key player in
this phenomenon, Ras has been implicated in the production
of another potent angiogenic factor interleukin-8 (Sparmann
and Bar-Sagi, 2004). Even if it was demonstrated that Ras
control IL-8 transcription, IL-8 mRNA 3-UTR contains nu-
merous AREs, suggesting that TTP could exert its anti-
angiogenic potential through VEGF as we demonstrated but
also by modulating IL-8 mRNA decay and consequently
production. To strengthen the relationship between VEGF
and TTP in the tumor development, it would have been
interested to demonstrate that exogenous VEGF reverses the
effect of TTP. However, this strategy would probably fail as
chronic exposition of animals to VEGF results in hepatic and
heart problems (Dor et al., 2002). Another potential of TTP
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consists on its ability to alter cell growth, because it modu-
lates Fos, Myc, and Cyclin D1 mRNA (Marderosian et al.,
2006; Hau et al., 2007). It could also induce apoptosis in
particular by modulation of the expression of TNF- (Johnson
et al., 2000; Johnson and Blackwell, 2002). We have never
observed that TTP affects the growth or apoptosis of the
Raf1-ER/TTP-Ras cells (Supplemental Figure 4SD). How-
ever, in our system, we do not know whether the decrease in
tumor size and vascularization involve apoptosis mecha-
nisms responsible for the reduction in the number of blood
vessels, because VEGF has been described as an antiapop-
totic factor for endothelial cells (Grosjean et al., 2006). Be-
cause many tumor cells were recently demonstrated to ex-
press VEGF receptors, down-regulation of VEGF production
could also result in apoptosis of the tumor cells by suppress-
ing an antiapoptotic autocrine loop. In conclusion, our study
suggests that TTP disappearance could represent a pertinent
diagnosis and prognosis marker for tumor aggressivity as
well as a potential indicator for the success of therapies in
tumors with increased ERKs activity.
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